Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;3(5):675-680.
doi: 10.3892/br.2015.486. Epub 2015 Jun 30.

Altered TNFAIP3 mRNA expression in peripheral blood mononuclear cells from patients with rheumatoid arthritis

Zhaoyan Wang  1 , Zongliang Zhang  2 , Jiangshui Yuan  1 , L I Li  1
Affiliations

Altered TNFAIP3 mRNA expression in peripheral blood mononuclear cells from patients with rheumatoid arthritis

Zhaoyan Wang et al. Biomed Rep. 2015 Sep.

Abstract

The tumor necrosis factor α-induced protein-3 (TNFAIP3) gene functions in negative immunoregulation and its single-nucleotide polymorphisms (SNPs) are associated with rheumatoid arthritis (RA) disease. However, its expression level in immune cells from RA patients remains unclear. The aim of the present study was to investigate whether the expression of TNFAIP3 is changed in patients with RA. Reverse transcription-quantitative polymerase chain reaction analysis was used to determine TNFAIP3 mRNA expression in peripheral blood mononuclear cells (PBMCs) from patients with RA and healthy controls. TNFAIP3 expression was decreased in RA patients compared with the healthy controls. The expression level of the TNFAIP3 gene negatively correlated with the RA score, anti-cyclic citrullinated peptide (CCP) antibody levels and C-reactive protein levels. Furthermore, RA patients with positive results of anti-CCP antibodies had a lower expression of TNFAIP3 than those without anti-CCP antibodies. In conclusion, the present results suggest that the insufficient expression of the TNFAIP3 gene in PBMCs may correlate with the diagnosis of RA.

Keywords: reverse transcription-quantitative polymerase chain reaction analysis; rheumatoid arthritis; tumor necrosis factor α-induced protein-3.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Tumor necrosis factor α-induced protein-3 (TNFAIP3) mRNA expression levels from rheumatoid arthritis (RA) patients and controls. Reverse transcription-quantitative polymerase chain reaction was performed to quantify the expression of the TNFAIP3 gene from RA patients (n=48) and controls (n=41). Horizontal lines indicate means (21.32 in the patient group; 52.58 in the control group). There is a significant decrease in TNFAIP3 expression in RA patients compared with that of the controls (P=0.0125).
Figure 2.
Figure 2.
Tumor necrosis factor α-induced protein-3 (TNFAIP3) mRNA expression levels in rheumatoid arthritis (RA) patients with and without anti-cyclic citrullinated peptide (CCP) antibodies (Ab). Reverse transcription-quantitative polymerase chain reaction was performed to quantify the expression of the TNFAIP3 gene from RA patients with (n=32) and without (n=16) anti-CCP Ab. Horizontal lines indicate means (19.44 in RA patients with anti-CCP Ab; 27.67 in RA patients without anti-CCP Ab). There is a significant decrease in TNFAIP3 expression in RA patients with positive anti-CCP Ab compared with those without anti-CCP Ab (P=0.0134).
Figure 3.
Figure 3.
Negative correlation between tumor necrosis factor α-induced protein-3 (TNFAIP3) mRNA expression levels and rheumatoid arthritis (RA) standard rating for all the RA patients (n=48).
Figure 4.
Figure 4.
Negative correlation between the tumor necrosis factor α-induced protein-3 (TNFAIP3) mRNA expression levels and anti-cyclic citrullinated peptide (CCP) antibody levels for the patients with a positive result of anti-CCP antibody (n=32).
Figure 5.
Figure 5.
Negative correlation between the tumor necrosis factor α-induced protein-3 (TNFAIP3) mRNA expression levels and C-reactive protein (CRP) levels for all the rheumatoid arthritis patients (n=48).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361. doi: 10.1038/nature01661. - DOI - PubMed
    1. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: Chemokines in the joints of patients. FEBS J. 2008;275:4448–4455. doi: 10.1111/j.1742-4658.2008.06580.x. - DOI - PubMed
    1. Li D, Wang L, Fan Y, Song L, Guo C, Zhu F, Zhang L, Shi Y. Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Clin Immunol. 2012;32:1287–1291. doi: 10.1007/s10875-012-9764-2. - DOI - PubMed
    1. Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31:769–779. doi: 10.1089/jir.2011.0029. - DOI - PMC - PubMed
    1. Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des. 2011;17:3141–3154. doi: 10.2174/138161211798157658. - DOI - PubMed